{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T16:17:34Z","timestamp":1768925854081,"version":"3.49.0"},"reference-count":14,"publisher":"Japanese Society of Internal Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,3,15]]},"DOI":"10.2169\/internalmedicine.8829-21","type":"journal-article","created":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T22:10:53Z","timestamp":1640643053000},"page":"903-906","source":"Crossref","is-referenced-by-count":15,"title":["Self-limited Polymyalgia Rheumatica-like Syndrome Following mRNA-1273 SARS-CoV-2 Vaccination"],"prefix":"10.2169","volume":"61","author":[{"given":"Shinji","family":"Izuka","sequence":"first","affiliation":[{"name":"Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Komai","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bunki","family":"Natsumoto","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Shoda","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keishi","family":"Fujio","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384: 403-416, 2021.","DOI":"10.1056\/NEJMoa2035389"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Liozon E, Parreau S, Filloux M, et al. Giant cell arteritis or polymyalgia rheumatica after influenza vaccination: a study of 12 patients and a literature review. Autoimmun Rev 20: 102732, 2021.","DOI":"10.1016\/j.autrev.2020.102732"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Manzo C, Natale M, Castagna A. Polymyalgia rheumatica as uncommon adverse event following immunization with COVID-19 vaccine: a case report and review of literature. Aging Med (Milton) 4: 234-238, 2021.","DOI":"10.1002\/agm2.12171"},{"key":"4","doi-asserted-by":"crossref","first-page":"105282","DOI":"10.1016\/j.jbspin.2021.105282","volume":"89","author":"S Cadiou","year":"2021","unstructured":"4. Cadiou S, Perdriger A, Ardois S, et al. SARS-CoV-2, polymyalgia rheumatica and giant cell arteritis: COVID-19 vaccine shot as a trigger? Comment on: &quot;Can SARS-CoV-2 trigger relapse of polymyalgia rheumatica?&quot; by Manzo et al. Joint Bone Spine 2021;88:105150. Joint Bone Spine 89: 105282, 2021.","journal-title":"Joint Bone Spine","ISSN":"https:\/\/id.crossref.org\/issn\/1297-319X","issn-type":"print"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Dasgupta B, Cimmino MA, Kremers HM, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative. Arthritis Rheum 64: 943-954, 2012.","DOI":"10.1016\/j.ymed.2012.09.009"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Bird HA, Esselinckx W, Dixon AS, Mowat AG, Wood PH. An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 38: 434-439, 1979.","DOI":"10.1136\/ard.38.5.434"},{"key":"7","unstructured":"7. Mettler C, Jonville-Bera A-P, Grandvuillemin A, Treluyer J-M, Terrier B, Chouchana L. Risk of giant cell arteritis and polymyalgia rheumatica following COVID-19 vaccination: a global pharmacovigilance study. Rheumatology (Oxford). Forthcoming."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Collier A-RY, Yu J, McMahan K, et al. Differential kinetics of immune responses elicited by COVID-19 vaccines. N Engl J Med 385: 2010-2012, 2021.","DOI":"10.1056\/NEJMc2115596"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Steensels D, Pierlet N, Penders J, Mesotten D, Heylen L. Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273. JAMA 326: 1533-1535, 2021.","DOI":"10.1001\/jama.2021.15125"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Camellino D, Matteson EL, Buttgereit F, Dejaco C. Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica. Nat Rev Rheumatol 16: 481-495, 2020.","DOI":"10.1038\/s41584-020-0458-5"},{"key":"11","doi-asserted-by":"crossref","first-page":"76","DOI":"10.5114\/reum.2020.95360","volume":"58","author":"P Falsetti","year":"2020","unstructured":"11. Falsetti P, Conticini E, Acciai C, et al. Polymyalgia rheumatica following infective triggersor vaccinations: a different subset of disease? Reumatologia\/Rheumatology 58: 76-80, 2020.","journal-title":"Reumatologia\/Rheumatology","ISSN":"https:\/\/id.crossref.org\/issn\/0034-6233","issn-type":"print"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Klimek L, Novak N, Cabanillas B, Jutel M, Bousquet J, Akdis CA. Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation. Allergy 76: 3307-3313, 2021.","DOI":"10.1111\/all.14794"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. DiPiazza AT, Leist SR, Abiona OM, et al. COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. Immunity 54: 1869-1882.e6, 2021.","DOI":"10.1016\/j.immuni.2021.06.018"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Dejaco C, Brouwer E, Mason JC, Buttgereit F, Matteson EL, Dasgupta B. Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. Nat Rev Rheumatol 13: 578-592, 2017.","DOI":"10.1038\/nrrheum.2017.142"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/6\/61_8829-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T03:32:22Z","timestamp":1647660742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/6\/61_8829-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,15]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.8829-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,15]]},"article-number":"8829-21"}}